CURRENT STATUS
AI-ECG detecting disease years before symptoms. CRISPR targeting PCSK9 for permanent cholesterol reduction. Base editing trials for hereditary cardiomyopathy. Cardiac regeneration via reprogramming entering early trials.
KEY BREAKTHROUGHS
Verve Therapeutics VERVE-102 — in vivo base editing to permanently lower cholesterol in one dose
AI-ECG detecting atrial fibrillation, heart failure, and valve disease from standard 12-lead ECGs
CRISPR knockout of PCSK9 in non-human primates showing durable 60% LDL reduction
Cardiac reprogramming — converting scar fibroblasts back into beating cardiomyocytes
AI-COMPRESSED PIPELINE
AI TOOLS ACCELERATING CURES
AI-ECG DiagnosticsCardiac Digital TwinsCRISPR Cholesterol EditingRegenerative Reprogramming AI
KEY ORGANIZATIONS
Verve TherapeuticsTenaya TherapeuticsRecursionMayo Clinic AIAstraZeneca
TIMELINE ESTIMATE
One-shot cholesterol cure: 2–3 years. Heart failure gene therapy: 4–6 years. Cardiac regeneration: 6–10 years.